公开(公告)号：US20240368127A1

公开(公告)日：2024-11-07

申请号：US18692305

申请日：2022-09-14

Applicant: FL2022-001, Inc.

Inventor： Johnny Y. Nagasawa ,  Iriny Botrous ,  Andiliy G. Lai ,  Andrew R. Hudson ,  Nicholas D. Smith ,  Steven P. Govek

IPC: C07D403/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4192 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K47/10 ,  A61K47/14 ,  A61K47/38 ,  C07D249/18 ,  C07D401/10 ,  C07D403/04 ,  C07D413/04 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04

Abstract: Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.

公开(公告)号：US20240246901A1

公开(公告)日：2024-07-25

申请号：US17929597

申请日：2021-03-10

Applicant: Sheldon Cao ,  Xiaolei Wang ,  Eubulus Biotherapeutics Inc.

Inventor： Sheldon Cao ,  Xiaolei Wang

IPC: C07C237/22 ,  A61K31/167 ,  A61K31/18 ,  A61K31/245 ,  A61K31/277 ,  A61K31/337 ,  A61K31/351 ,  A61K31/36 ,  A61K31/365 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/5377 ,  A61P35/00 ,  C07C255/60 ,  C07C311/08 ,  C07C311/16 ,  C07C317/40 ,  C07D213/56 ,  C07D213/64 ,  C07D213/89 ,  C07D231/56 ,  C07D249/18 ,  C07D271/12 ,  C07D277/64 ,  C07D285/14 ,  C07D303/04 ,  C07D305/06 ,  C07D309/06 ,  C07D309/14 ,  C07D317/66 ,  C07D333/24 ,  C07D405/12 ,  C07D407/12

CPC classification number: C07C237/22 ,  A61K31/167 ,  A61K31/18 ,  A61K31/245 ,  A61K31/277 ,  A61K31/337 ,  A61K31/351 ,  A61K31/36 ,  A61K31/365 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/5377 ,  A61P35/00 ,  C07C255/60 ,  C07C311/08 ,  C07C311/16 ,  C07C317/40 ,  C07D213/56 ,  C07D213/64 ,  C07D213/89 ,  C07D231/56 ,  C07D249/18 ,  C07D271/12 ,  C07D277/64 ,  C07D285/14 ,  C07D303/04 ,  C07D305/06 ,  C07D309/06 ,  C07D309/14 ,  C07D317/66 ,  C07D333/24 ,  C07D405/12 ,  C07D407/12 ,  C07C2601/02 ,  C07C2601/14

Abstract: Provided herein are GPX4 inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition.

公开(公告)号：US12024529B2

公开(公告)日：2024-07-02

申请号：US18313703

申请日：2023-05-08

Applicant: AMGEN INC.

Inventor： Robert Farrell

IPC: C07D249/18 ,  C07C59/56 ,  C07C59/68 ,  C07C311/11 ,  C07D498/00 ,  C07D513/08 ,  C07D513/10

CPC classification number: C07D513/10 ,  C07C59/56 ,  C07C59/68 ,  C07C311/11 ,  C07D249/18 ,  C07D498/00 ,  C07D513/08

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,




and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

公开(公告)号：US20240116882A1

公开(公告)日：2024-04-11

申请号：US18274867

申请日：2022-01-28

Applicant: TXINNO BIOSCIENCE INC.

Inventor： Chan Sun Park ,  Sung Joon Kim ,  Ali Imran ,  Yoo Jin Na ,  So Ra Paik ,  Jung Hwan Choi ,  Sun Woo Lee ,  Yong Yea Park ,  Ah Ran Yu ,  Sun Young Park

IPC: C07D249/18 ,  C07D401/04

CPC classification number: C07D249/18 ,  C07D401/04

Abstract: The present invention relates to a novel benzotriazole derivative compound, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, which are related to a compound for inhibiting ENPP1, a composition for inhibiting ENPP1, and a method for inhibiting ENPP1.

公开(公告)号：US20240067614A1

公开(公告)日：2024-02-29

申请号：US18023558

申请日：2021-09-01

Applicant: NRG Therapeutics Ltd.

Inventor： Neil MILLER ,  Richard RUTTER ,  Jan KULAGOWSKI ,  Richard MORPHY ,  Tammy LADDUWAHETTY ,  John MACLEAN ,  Mustafa MOROGLU ,  Eric TALBOT ,  Michael ROWLEY

IPC: C07D249/18 ,  C07D277/68 ,  C07D209/34 ,  C07D209/96 ,  C07D263/58 ,  C07D235/26 ,  C07D231/56 ,  C07D405/12

CPC classification number: C07D249/18 ,  C07D277/68 ,  C07D209/34 ,  C07D209/96 ,  C07D263/58 ,  C07D235/26 ,  C07D231/56 ,  C07D405/12

Abstract: The invention relates to compounds of formula (I): and related aspects.

公开(公告)号：US11787791B2

公开(公告)日：2023-10-17

申请号：US17279382

申请日：2019-09-27

Applicant: ACUCELA INC.

Inventor： Mark W. Orme ,  Edison S. Zuniga ,  Vladimir A. Kuksa ,  Russell Stuart Craft ,  Eduardo Moreno Saveedra ,  Johannes Wilhelm Georg Meissner ,  Jacobus Antonius Joseph den Hartog ,  Albert Cornelis Dros

IPC: C07D413/12 ,  C07D235/08 ,  C07D249/18 ,  C07D261/20 ,  C07D263/56 ,  C07D263/58 ,  C07D277/64 ,  C07D277/82 ,  C07D413/04 ,  C07D491/107

CPC classification number: C07D413/12 ,  C07D235/08 ,  C07D249/18 ,  C07D261/20 ,  C07D263/56 ,  C07D263/58 ,  C07D277/64 ,  C07D277/82 ,  C07D413/04 ,  C07D491/107

Abstract: Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

公开(公告)号：US20220388995A1

公开(公告)日：2022-12-08

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC: C07D409/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20220298173A1

公开(公告)日：2022-09-22

申请号：US17579457

申请日：2022-01-19

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Roland Gendron ,  Melissa Fleury ,  Adam D. Hughes

IPC: C07D498/08 ,  C07D213/81 ,  C07D231/14 ,  C07D233/26 ,  C07D233/90 ,  C07D237/24 ,  C07D239/34 ,  C07D241/24 ,  C07D249/04 ,  C07D249/10 ,  C07D249/18 ,  C07D257/04 ,  C07D261/20 ,  C07D263/34 ,  C07D271/06 ,  C07D277/56 ,  C07D307/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D409/06 ,  C07D471/04 ,  C07D498/04 ,  C07D261/18 ,  C07D207/34 ,  C07D239/36 ,  C07D413/06 ,  A61K31/42 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/12 ,  C07D213/79 ,  C07D213/80 ,  C07D237/04 ,  C07D249/08 ,  C07D249/12 ,  C07D261/12 ,  C07D263/56 ,  C07D277/46 ,  C07D333/40

Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US20220281802A1

公开(公告)日：2022-09-08

申请号：US17631972

申请日：2020-07-31

Applicant: Beth Israel Deaconess Medical Center, Inc.

Inventor： Leena PRADHAN-NABZDYK ,  Lijun SUN ,  Philip LOGERFO ,  Finith JERNIGAN ,  Gabriel BIRANNE ,  Frank W. LOGERFO

IPC: C07C211/45 ,  C07D249/18 ,  C07C279/18 ,  C07D401/04

Abstract: Compounds, pharmaceutical compositions, and methods are disclosed for inhibiting interaction between IL18 and IL18R.

公开(公告)号：US20220194939A1

公开(公告)日：2022-06-23

申请号：US17603988

申请日：2020-04-17

Applicant: Colorado Research Partners, LLC ,  The Regents of the University of Colorado, A Body Corporate

Inventor： Sundeep Dugar ,  Chase Needham ,  Paul Maffuid ,  Rajendra Kumar Reddy Gadikota ,  Sreenivasulu Reddy Koduru ,  Michael F. Wempe ,  Vijay Kumar

IPC: C07D471/04 ,  C07D231/56 ,  A61K45/06 ,  C07D403/12 ,  C07D401/12 ,  C07D249/18

Abstract: Disclosed herein are novel compounds that inhibit fructokinase (KHK or ketohexokinase) and the downstream metabolic effects mediated by fructose metabolism. Fructokinase inhibitors specifically block the metabolism of both dietary and endogenous fructose metabolism and have a host of potential metabolic benefits.